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SUMMARY
Characteristics of transformed and tumor cells
include increased levels of protein synthesis and
elevated expression of RNA polymerase (pol) III
products, such as tRNAs and 5S rRNA. However,
whether deregulated pol III transcription contributes
to transformation has been unclear. Generating cell
lines expressing an inducible pol III-specific tran-
scription factor, Brf1, allowed us to raise tRNA and
5S rRNA levels specifically. Brf1 induction caused
an increase in cell proliferation and oncogenic trans-
formation, whereas depletion of Brf1 impeded trans-
formation. Among the gene products induced byBrf1
is the tRNAi
Met that initiates polypeptide synthesis.
Overexpression of tRNAi
Met is sufficient to stimulate
cell proliferation and allow immortalized fibroblasts
to form foci in culture and tumors in mice. The data
indicate that elevated tRNA synthesis can promote
cellular transformation.
INTRODUCTION
Cell-cycle progression requires attainment of adequate mass
(Brooks, 1977; Johnston et al., 1977). Since most of a cell’s
dry mass is protein, the rate of protein accumulation is a funda-
mental determinant of cell growth and proliferation rates
(Zetterberg and Killander, 1965). This may explain why elevated
protein synthesis is strongly linked to cancer (Bjornsti and
Houghton, 2004; Mamane et al., 2004; Pandolfi, 2004; Ruggero
and Pandolfi, 2003). Components of the translation machinery
are commonly deregulated in cancers, and in several cases the
oncogenicity of these events has been established through
genetics or the use of animal models (Bjornsti and Houghton,
2004; Mamane et al., 2004; Pandolfi, 2004; Ruggero and
Pandolfi, 2003). Tumours display both quantitative and qualita-
tive changes in protein expression, with preferential translation
of some mRNAs encoding growth-promoting proteins (Mamane
et al., 2004; Pandolfi, 2004).
Translation depends on tRNA and 5S rRNA, short abundant
transcripts that are made by pol III. Overexpression of these
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transformed cell, such as ovarian carcinomas (Winter et al.,
2000; White, 2004). A partial explanation for this abnormal eleva-
tion is that the pol III-specific transcription factor TFIIIB is bound
and repressed in healthy cells by the tumor suppressors RB and
p53 (Felton-Edkins et al., 2003b; White, 2005). Since the function
of p53 and/or RB is compromised in most cancers (Evan and
Vousden, 2001; Hanahan and Weinberg, 2000), TFIIIB may be re-
leased from restraint in a high proportion of malignancies. Evi-
dence for this has come from several studies. For example, the
ability of RB to inhibit pol III output is compromised by cancer-
derived mutations (Felton-Edkins et al., 2003b; White, 2004;
White et al., 1996). Pol III transcription is stimulated by viral on-
coproteins that bind and neutralize RB (Larminie et al., 1999; Sut-
cliffe et al., 1999; White et al., 1996; Felton-Edkins and White,
2002). Furthermore, inactivation of RB through deregulated
phosphorylation releases TFIIIB and raises pol III output (Scott
et al., 2001). Similarly, genetic mutation of p53 or overexpression
of the oncoproteins E6 and Mdm2 also result in elevated pol III
transcription (Morton et al., 2007; Stein et al., 2002). In addition,
TFIIIB is bound and activated by the proto-oncogene product
c-Myc, which is overexpressed in many cancers (Felton-Edkins
et al., 2003b; Gomez-Roman et al., 2003). TFIIIB activity is also
stimulated through direct phosphorylation by Erk kinases, which
are abnormally active in 30% of human tumors due to onco-
genic mutations in Ras or Raf that lie upstream of Erk in the
MAP kinase cascade (Felton-Edkins et al., 2003a). Clearly, TFIIIB
is subject to powerful regulatory influences that frequently go
awry during cell transformation.
RB, p53, Erk, and c-Myc all have multiple targets and pleiotro-
pic effects. It could therefore be argued that elevated pol III tran-
scription is a side effect of their deregulation, perhaps with little
impact or significance. However, such an argument cannot ex-
plain an unrelated mechanism that also raises pol III output in
some transformed cell types. TFIIIC, a factor essential for tRNA
and 5S rRNA synthesis, is induced at both the mRNA and protein
levels in cells transformed by SV40, polyomavirus, and Epstein
Barr virus (Felton-Edkins et al., 2006; Felton-Edkins and White,
2002). This is not a secondary response to accelerated prolifer-
ation because TFIIIC levels are not influenced by growth factor
availability or cell-cycle arrest (Scott et al., 2001; Winter et al.,
2000). Similar deregulation was found in biopsies from ovarian
cancer patients (Winter et al., 2000). The DNA-binding activity
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with grade 2 or 3 ovarian carcinomas; in every case, the tumor
had higher TFIIIC activity than healthy ovarian tissue from the
same patient (Winter et al., 2000). RT-PCR revealed that the
tumors overexpress mRNAs encoding all five subunits of TFIIIC,
while control mRNAs remained at normal levels (Winter et al.,
2000). The fact that all five subunits of TFIIIC were elevated in
each case examined makes it extremely unlikely that this is a
random effect. These observations provided evidence that
a pol III-specific factor is overproduced in a human cancer. Since
TFIIIC is dedicated exclusively to pol III transcription, this implies
a specific drive to raise pol III output as the cancer develops.
Despite significant progress in understanding the molecular
basis of pol III activation in cancers, the phenotypic conse-
quences have remained a matter of conjecture. Here we address
this issue directly by specifically inducing pol III transcripts inde-
pendently of the many confusing genetic and epigenetic
changes that normally accompany cell transformation. To this
end, we have examined the effects of raising levels of the pol
III-specific transcription factor Brf1, an essential subunit of
TFIIIB. Induction of Brf1 results in a highly specific elevation of
tRNA and 5S rRNA expression in both fibroblast and ovarian
epithelial cell lines. This is accompanied by a substantial in-
crease in the rate of protein synthesis. Under these conditions,
cell-cycle progression and cell proliferation are stimulated
markedly. Furthermore, cells treated in this way manifest charac-
teristic features of oncogenic transformation, including focus
formation, loss of anchorage dependence, and tumorigenicity,
when injected into mice. The response to Brf1 can be curtailed
by using RNAi to achieve partial knockdown of a pol III subunit.
Furthermore, overexpression of the pol III-transcribed tRNAi
Met
gene can itself be sufficient to drive proliferation and induce
tumors in mice. The data suggest that pol III activation can
have profound and unexpected consequences that may contrib-
ute significantly toward cancer.
RESULTS
Induction of Brf1 Stimulates Pol III
Transcription Specifically
TFIIIB is necessary and sufficient to recruit pol III to its genetic
templates (Kassavetis et al., 1990). It is composed of three
essential subunits, TBP, Bdp1, and either Brf1 or the related
subunit Brf2 (Schramm and Hernandez, 2002). To stimulate pol
III transcription specifically, we created stably transfected lines
of immortalized mouse embryonic fibroblasts carrying cDNA
encoding Brf1 (Brf1.MEFs). A Tet-Off system was used in which
expression of Brf1 mRNA can be induced by withdrawing doxy-
cycline from the culture medium (Figure 1A). This results in
a modest increase in the level of Brf1 protein (Figure 1B). TBP
and Bdp1 levels show little or no change under these circum-
stances. Nevertheless, Brf1 induction raises expression of 5S
rRNA and various tRNAs, an effect not seen when control clones
(vec.MEFs) carrying empty vector are treated in the same way
(Figure 1C and Figure S1 available online). Brf1 also stimulates
expression of pol III transcripts from B2 short interspersed
repeats (SINEs), which are tRNA-derived pseudogenes (Daniels
and Deininger, 1985). However, the response is highly selective
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levels of U6, 7SK, and MRP RNAs are not elevated, which is con-
sistent with the fact that expression of these products requires
Brf2 instead of Brf1 (Schramm et al., 2000). Thus, chromatin
immunoprecipitation (ChIP) shows little or no binding of Brf1 at
7SK genes, even when it is overexpressed (Figure 1D). In con-
trast, Brf1 is clearly detected at tRNA and 5S rRNA genes and
its occupancy increases after removal of doxycycline. ChIP
also confirms that Brf1 induction stimulates recruitment of pol
III to tRNA and 5S, but not 7SK genes. In contrast to 7SK, both
Brf1 and pol III are recruited to 7SL genes following doxycycline
withdrawal (Figure 1D). Degradation of surplus transcript might
account for the fact that 7SL RNA does not increase under these
circumstances (Figure 1C).
The data show that Brf1 induction can elicit a highly specific
increase in expression of a subset of pol III products. Further
evidence of specificity is provided by the pol I-dependent rRNAs
(5.8S, 18S, and 28S) and the pol II-dependent mRNAs encoding
TBP, Bdp1, TK, and ARPP P0, all of which remain at near
constant levels (Figures 1A and 1C). Expression of unprocessed
precursor rRNAs is also unaltered (Figure S2).
Induction of Brf1 Can Stimulate Protein Synthesis
Since tRNAs and 5S rRNA are essential components of the
protein synthetic machinery, their elevated expression following
Brf1 induction might influence the rate of translation. That this is
the case was shown by measuring incorporation of radioactive
amino acids into newly synthesized polypeptides (Figure 2A).
Protein synthesis had risen substantially after 3 days of Brf1
induction, an effect not seen when empty vector control clones
were treated in the same way. Accordingly, the overall accumu-
lation of protein is significantly higher with elevated Brf1
(Figure 2B). We conclude that the specific induction of Brf1,
and hence tRNA and 5S rRNA, is accompanied by a marked
increase in protein synthesis. This can be explained if Brf1 is con-
trolling production of something that is rate limiting for translation.
Elevated translational activity is not expected to increase
synthesis of all proteins uniformly; preferential induction is often
seen from mRNAs with complex secondary structures in their
50-untranslated regions (Koromilas et al., 1992; Mamane et al.,
2004). Examples are provided by cyclin D1 and c-Myc, both of
which are subject to translational regulation (Mamane et al.,
2004). Induction of Brf1 produced a selective increase in expres-
sion of these proteins without altering the levels of their mRNAs
(Figure 2C). We conclude that elevated Brf1 can trigger both
qualitative and quantitative changes in protein synthesis.
Induction of Brf1 Can Promote Cell-Cycle
Progression and Proliferation
Despite the clear increase in protein production, cell volume
showed little change in response to Brf1. Indeed, normalization
to cell number revealed that the protein content of each cell
had risen only marginally (Figure 2D). This clearly suggested
a proliferative response, such that the accumulation of protein
is balanced within a population by an increase in cell number.
Precedent for such effects is provided by certain translation
factors, activation of which can be sufficient to trigger cell prolif-
eration, presumably due to elevated rates of protein synthesis
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Figure 1. Induction of Brf1 Stimulates tRNA and 5S rRNA Expression Selectively
(A) RT-PCR of the indicated mRNAs from a vec.MEF clone (lanes 1 and 2) and two Brf1.MEF clones (lanes 3–6) after 48 hr with (odd lanes) or without (even lanes)
doxycycline.
(B) Immunoblot of Brf1, Bdp1, TBP, and actin in vec.MEF (lanes 1 and 2) and two Brf1.MEF clones (lanes 3–6) after 48 hr with (odd lanes) or without (even lanes)
doxycycline.
(C) RT-PCR of the indicated transcripts from a vec.MEF clone (lanes 1 and 2) and two Brf1.MEF clones (lanes 3–6) after 48 hr with (odd lanes) or without (even
lanes) doxycycline.
(D) ChIP assay to test occupancy of TAFI48 (lanes 5 and 6), TFIIB (lanes 7 and 8), pol III (lanes 9 and 10), and Brf1 (lanes 11 and 12) at the indicated genes in Brf1.MEFs
after 48 hr with (odd lanes) or without (even lanes) doxycycline. Input lanes show product intensities obtained using 10% (lanes 1 and 2) or 1% (lanes 3 and 4) of input.
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1990; Mayeur and Hershey, 2002). We therefore investigated if
Brf1 has a similar effect.
Equal numbers of Brf1.MEF or vec.MEF cells were plated in
the presence or absence of doxycycline. Initial rates of prolifera-80 Cell 133, 78–89, April 4, 2008 ª2008 Elsevier Inc.tion were similar in all cases, but after 3 days the cells with ele-
vated Brf1 began to proliferate faster than the other populations.
By 5 days after plating in the absence of doxycycline, the number
of Brf1.MEFs had reached approximately twice that seen in the
presence of doxycycline or with vec.MEF controls (Figure 3A).
This dramatic effect was not a peculiarity of an individual clone
but has been observed with eight independent clones of
Brf1.MEFs. It can also be obtained using an adenovirus vector
that produces Brf1. Thus, immortalized MEFs infected with
Brf1-expressing adenovirus proliferate more rapidly than the
same MEFs infected with a control adenovirus that encodes
GFP (Figure 3B).
Accelerated rates of cell-cycle progression or diminished rates
of cell death might be responsible for the effect of Brf1 induction
on population numbers. FACS analysis of relative DNA content
was used to examine these features (Figures 3C and S3). Only
a small proportion of cells in each population was found to
have a sub-G1 content of DNA, which is indicative of apoptosis.
Figure 2. Induction of Brf1 Stimulates Protein
Synthesis
(A) Incorporation of 35S-labeled methionine and cysteine into
newly synthesized polypeptides in Brf1.MEFs and vec.MEF
controls. Values are means ± standard deviation of three sep-
arate experiments, each with three replicates per condition.
(B) After 4 days with or without doxycycline, total protein
content was measured for vec.MEF and Brf1.MEF cultures.
Values are means ± standard deviation (SD) of three separate
experiments.
(C) Immunoblot of protein levels (left panel) and RT-PCR of
mRNA levels (right panel) for cyclin D1, c-Myc, and actin in
vec.MEF (lanes 1 and 2) and two Brf1.MEF clones (lanes
3–6) after 48 hr with (odd lanes) or without (even lanes)
doxycycline.
(D) After 4 days with or without doxycycline, total protein
content was measured for vec.MEF and Brf1.MEF cultures
and adjusted for cell number to give protein/cell. Values are
means ± SD of three separate experiments.
Although this fraction was suppressed further when
Brf1 was induced, so few cells were apoptotic that
this could not account for the overall increase in
numbers. Far more substantial changes were
seen in the cell-cycle distribution of the viable
Brf1.MEFs. Thus, the fraction of cells in G0/G1
phase decreased from 58% to 40% after Brf1 in-
duction, whereas the fraction in S phase increased
from 26% to 36%. In contrast, doxycycline with-
drawal had little effect on vec.MEF controls. We
conclude that Brf1 can stimulate cell-cycle
progression.
Brf1 Can Increase Proliferation in Several
Cell Types
As with immortalized MEFs, IMR90 human diploid
fibroblasts proliferate more rapidly when infected
with adenoviral Brf1 expression vector, compared
with cells infected with control adenovirus express-
ing GFP (Figure 4A). The proliferative response to
elevated Brf1 is therefore not confined to rodent
fibroblasts. The effect is transient with adenovirus
due to rapid depletion of exogenous Brf1 from
proliferating cells (Figure 4A, lower panels).
To determine if this response can also be obtained in epithelial
cells, we used the Tet-Off system to produce stably transfected
lines of CHO cells in which expression of exogenous Brf1 can be
controlled with doxycycline (Figure 4B). As in MEFs, mild induc-
tion of Brf1 in CHO cells selectively raises expression of a subset
of pol III transcripts, including tRNA and 5S rRNA (Figure 4C).
Furthermore, it again exerts a strong stimulatory effect on cell
proliferation (Figure 4D). Four independent clones of Brf1.CHO
cells were tested in this way, and in each case doxycycline
withdrawal was found to confer a marked proliferative advan-
tage. We conclude that elevated levels of the pol III transcription
factor Brf1 can be sufficient to drive proliferation of mammalian
fibroblasts or epithelial cells.
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Activation of Pol III Transcription Is Required
for Brf1 to Stimulate Proliferation
As part of TFIIIB, Brf1 associates with several regulatory factors
that can have a profound influence on cell proliferation, including
p53, RB, TBP, c-Myc, and Erk (Felton-Edkins et al., 2003b;
White, 2005). This raises the possibility that the effects of Brf1
induction may reflect sequestration of one or more of these
key regulators. This is unlikely to be the case for p53 because
it contacts the TBP subunit of TFIIIB rather than Brf1 (Crighton
et al., 2003). Overexpressing Brf1 might have been predicted
to sequester TBP away from SL1 and TFIID complexes, thereby
reducing transcription by pols I and II. However, the constant
expression of several mRNAs and rRNAs seen in Figure 1B
Figure 3. Brf1 Can Stimulate Cell Proliferation
(A) Cell number counts over 5 days after plating of Brf1.MEFs or vec.MEFs
cultured in the presence or absence of doxycycline. Mean cell numbers are
plotted ± SD for three independent vec.MEF clones and four independent
Brf1.MEF clones.
(B) Cell number counts over 4 days after infection of MEFs with adenovirus
expressing Brf1 or GFP. Mean cell numbers are plotted ±SD for three indepen-
dent experiments.
(C) Relative proportions of MEFs in different cell-cycle phases 48 hr after
plating, as determined by flow cytometry of relative DNA content.R
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effects. Brf1 is bound directly by c-Myc, Erk, and CK2, but
sequestration of any of these mitogenic proteins would be
expected to inhibit rather than stimulate proliferation. In contrast,
sequestration of RB might be predicted to produce this
response. Since RB interacts with Brf1 (Chu et al., 1997; Hirsch
et al., 2004; Larminie et al., 1997), we investigated expression of
the E2F-regulated genes encoding DHFR, B-Myb, and p107,
which are known to be repressed by the RB family in MEFs
(Hurford et al., 1997). However, the mRNAs encoded by these
genes did not respond to induction of Brf1 (Figure 5A). This
suggests that levels of Brf1 in our clones are insufficient to trigger
a general deregulation of RB target genes, although more
selective changes cannot be excluded.
Brf1 is considered to be a pol III-specific transcription factor,
but we cannot exclude the possibility that it has additional func-
tions that remain to be discovered. We therefore tested if the abil-
ity of Brf1 to drive proliferation requires its well-characterized role
in pol III transcription. RPC39 is a specific subunit of pol III that in-
teracts with Brf1 in order to recruit the polymerase to its genetic
templates (Schramm and Hernandez, 2002). RNAi was used to
reduce the level of RPC39 in Brf1.MEFs. In the presence of doxy-
cycline (Brf1 not induced), partial depletion of RPC39 in this way
had minimal effect on tRNA expression or proliferation, implying
that RPC39 is in relative excess (Figure 5B). However, when
RPC39 levels are restricted in this way, there is insufficient active
pol III to support increased tRNA expression after withdrawal of
doxycycline and the proliferative response to Brf1 induction is
blocked (Figure 5C). This is unlikely to be due to any off-target ef-
fect, as the same response was obtained with alternative siRNAs
against different parts of the RPC39 sequence. These data pro-
vide evidence that Brf1 cannot stimulate cell proliferation when
pol III transcription is prevented from rising.
Brf1 Induction Can Transform Cells
Induction of Brf1 is accompanied by morphological changes that
are often seen in transformed cells, as well as focus formation
and increased saturation density (Figures 6A and 6B). Such
changes were not observed with empty vector control clones.
To test for anchorage dependence, we assayed for colony
formation in soft agar (Figures 6C and S4). As expected,
vec.MEF and vec.CHO controls produced no macroscopic
colonies. In contrast, Brf1.MEF and Brf1.CHO clones were
able to form colonies, but only in the absence of doxycycline.
Brf1 induction can therefore compromise contact inhibition
and allow anchorage-independent colonies to form.
Since these observations suggest that Brf1 can have
transforming properties, we tested for tumor formation in mice.
Two independent clones of Brf1.MEFs were injected into mice,
in parallel with two independent vec.MEF clones and a
Ras-transformed line as positive control. Both Brf1.MEF clones
caused tumors, albeit less rapidly than the Ras-transformed
positive control (Figure 6D). All 15 mice that received Brf1.MEFs
developed tumors within 3 months of injection. In contrast, none
of the 10 mice injected with vec.MEF control cells had tumors
after 6 months, when the experiment was terminated. These
data provide evidence that elevated Brf1 levels can cause
oncogenic transformation in vivo.
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model of tumorigenesis. Loss of p53 is a common step in the
development of colon cancer (Kinzler and Vogelstein, 1996).
This can be mimicked using the HCT116 colon carcinoma cell
line and a derivative with targeted disruption of both p53 alleles
(Bunz et al., 1998). The p53 null cells form large foci that are not
observed with the p53-positive cells (Figure 6E). Focus formation
in this model can be severely impaired by RNAi-mediated deple-
tion of c-Myc, a key player in colon carcinogenesis (Sansom
et al., 2007). Similarly, siRNAs directed against the Brf1 message
were found to inhibit focus formation (Figure 6E).
Figure 4. Brf1 Can Stimulate the Prolifera-
tion of Several Cell Types
(A) Cell number counts over 4 days after infection
of IMR90 fibroblasts with adenovirus expressing
HA-tagged Brf1 or GFP. Mean cell numbers are
plotted ± SD for two independent experiments.
An immunoblot probed with antibodies against
Brf1 (upper panel), HA, and actin (lower panel) is
shown underneath.
(B) Immunoblot to compare levels of Brf1 and actin
in extracts of vec.CHO (lanes 1 and 2) and three
Brf1.CHO clones (lanes 3–8) after 48 hr in the
presence (odd lanes) or absence (even lanes) of
doxycycline.
(C) RT-PCR analysis of levels of the indicated
transcripts in a vec.CHO clone (lanes 1 and 2)
and two Brf1.CHO clones (lanes 3–6) after 48 hr
in the presence (odd lanes) or absence (even
lanes) of doxycycline.
(D) Cell number counts over 5 days after plating of
Brf1.CHOs or vec.CHOs cultured in the presence
or absence of doxycycline. Mean cell numbers
are plotted ± standard deviation for three indepen-
dent vec.CHO clones and three independent
Brf1.CHO clones.
Elevated Expression of tRNAi
Met
Can Stimulate Proliferation
Among the targets of Brf1 are the genes
encoding tRNAi
Met, the tRNA required
for polypeptide chain initiation. We con-
structed clones of immortalized MEFs
that carry stably transfected copies of
a plasmid containing this gene. RT-
PCR confirmed that levels of tRNAi
Met
are modestly raised in these clones,
without exceeding the physiological
range (Figure 7A). The overall rate of
translation is significantly elevated in
these clones (Figure 7B). As in
Brf1.MEFs, expression of c-Myc and
cyclin D1 proteins increase without a
corresponding change in their mRNAs
(Figures 7A and 7C). Raising tRNAi
Met
can therefore cause quantitative and
qualitative changes in protein expres-
sion. These effects are selective, as
they are not seen in MEFs treated in the same way with plasmid
carrying an elongator tRNAe
Met gene. Counts of cell number
revealed that tRNAi
Met elicits a consistent increase in the rate
of proliferation (Figure 7D). This effect was seen with each of
four independent tRNAi
Met.MEF lines. Thus, the proliferative
response to Brf1 can be recapitulated by raising the expression
of one of its pol III-transcribed targets. MEFs transfected with
the tRNAe
Met gene showed no consistent change in prolifera-
tion relative to empty vector controls.
We were surprised to observe that tRNAi
Met.MEFs form
foci (Figure 7E). Two independent clones were therefore
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Figure 5. Induction of Proliferation by Brf1 Requires Elevated Pol III Transcription
(A) RT-PCR to compare levels of the indicated transcripts from a vec.MEF clone (lanes 1 and 2) and two Brf1.MEF clones (lanes 3–6) after 48 hr in the presence
(odd lanes) or absence (even lanes) of doxycycline.
(B) Brf1.MEFs were cultured for 5 days in the presence of doxycycline and transfected after 72 hr with the indicated siRNAs. Panels on the left show levels of
RPC39 and actin protein, as determined by western blot (upper two panels) and levels of RPC39 mRNA, tRNAi
Met, and ARPP P0 mRNA, as determined by
RT-PCR (lower three panels). Graph shows mean numbers of viable cells ± SD for two independent experiments.
(C) Brf1.MEFs were cultured for 5 days with (lane 1) or without (lanes 2–4) doxycycline and transfected after 72 hr with the indicated siRNAs. Panels on the left
show levels of Brf1, RPC39, and actin protein, as determined by western blot (upper 3 panels) and levels of RPC39 mRNA, tRNAi
Met, and ARPP P0 mRNA, as
determined by RT-PCR (lower 3 panels). Graph shows mean numbers of viable cells ± standard deviation for two independent experiments.
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vector. Also included was a tRNAe
Met.MEF line, which did
not show enhanced translation, proliferation, or focus forma-
tion. All five mice receiving the Ras-transformed positive
control line developed tumors within 4 weeks of injection.
At this time, tumors were not visible in any of the other
mice. However, tumors began to appear by week 6 in84 Cell 133, 78–89, April 4, 2008 ª2008 Elsevier Inc.mice carrying tRNAi
Met.MEFs, and 9 out of 10 of these
mice had tumors by week 12 (Figure 7F). In contrast, no
tumors were detected in the 15 mice injected with vec.MEF
or tRNAe
Met.MEF cells, even after 7 months, when the exper-
iment was terminated. These data provide evidence that
elevated expression of tRNAi
Met can confer tumorigenicity
on immortalized MEFs.
Figure 6. Induction of Brf1 Can Transform Cells
(A) Focus formation in MEF or CHO clones after 3 weeks in the presence or absence of doxycycline, as indicated.
(B) Mean numbers of confluent MEFs ± SD after 3 weeks in the presence or absence of doxycycline. Data are for two independent experiments.
(C) Mean numbers of colonies ± SD formed by a vec.CHO clone, two independent Brf1.CHO clones, a vec.MEF clone, and two independent Brf1.MEF clones
cultured for 3–4 weeks in soft agar. Data shown are for three independent experiments.
(D) Mice were injected with Ras-transformed MEFs, two independent vec.MEF clones, and two independent Brf1.MEF clones. The number of mice that
developed tumors and the latency of onset are indicated in each case.
(E) Matched p53+/+ or p53/ HCT116 cells were transfected with the indicated siRNAs. Panels on the right show levels of Brf1 and actin protein, as determined by
western blot. Graph shows mean numbers of large foci (>3 mm diameter) ± SD for two independent experiments.
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Overexpression of pol III transcripts has long been associated
with cancer (White, 2004). Our data provide evidence that thiscan, at least in certain contexts, be sufficient to drive proliferation
and oncogenic transformation. This has been demonstrated by
artificially raising levels of the Brf1 subunit of TFIIIB, which results
in enhanced recruitment of pol III to tRNA and 5S rRNA genesCell 133, 78–89, April 4, 2008 ª2008 Elsevier Inc. 85
in vivo, thereby increasing their expression. Furthermore, the
phenotypic effects of Brf1 induction can be mimicked by elevated
levels of the pol III product tRNAi
Met. The data suggest that activa-
tion of pol III transcription, so often observed in transformed cells,
canhave functional consequences for thedevelopmentof cancer.
There is already considerable evidence that hyperactivity of
the translation machinery can cause proliferation and cell trans-
formation (Bjornsti and Houghton, 2004; Mamane et al., 2004;
Ruggero and Pandolfi, 2003). Most pertinent to our findings is
the oncogenicity of eEF1A (formerly known as EF-1a), which
controls the recruitment of amino-acylated tRNA to the ribosome
(Anand et al., 2002; Tatsuka et al., 1992; Tomlinson et al., 2005).
When overexpressed in fibroblasts, eEF1A can stimulate prolif-
eration and allow formation of colonies in soft agar and tumors
in nude mice (Anand et al., 2002). Furthermore, it is upregulated
in human ovarian and breast carcinomas, often due to gene
amplification (Anand et al., 2002; Tomlinson et al., 2005). A
tRNA methyltransferase called Misu is overexpressed in breast
and colon cancers, and RNAi of Misu inhibits growth of carcino-
Figure 7. Elevated Expression of tRNAi
Met
Can Stimulate Protein Synthesis, Prolifera-
tion, and Focus Formation
(A) RT-PCR to compare levels of the indicated
transcripts in MEF clones transfected with empty
vector (lane 1), tRNAi
Met (lane 2), and tRNAe
Met
(lane 3) constructs.
(B) Incorporation of 35S-Met and 35S-Cys into
newly synthesized polypeptides in MEFs trans-
fected with empty vector, tRNAi
Met, or tRNAe
Met.
Values are means ± SD of two separate experi-
ments, each with two independent vector clones,
four independent tRNAi
Met clones, and two inde-
pendent tRNAe
Met clones.
(C) Western blot to compare levels of c-Myc,
cyclin D1, and actin proteins in MEF clones trans-
fected with empty vector (lane 1), tRNAi
Met (lane 2),
and tRNAe
Met (lane 3) constructs.
(D) Cell number counts over 4 days after plating of
MEFclones transfectedwithemptyvector, tRNAi
Met,
or tRNAe
Met constructs. Values are means ± SD of
two separate experiments, each with two indepen-
dent vector clones, four independent tRNAi
Met
clones, and two independent tRNAe
Met clones.
(E) Duplicate focus formation assays with MEF
clones transfected with empty vector, tRNAi
Met, or
tRNAe
Met constructs.
(F) Mice were injected with Ras-transformed MEFs,
two independent clones of vec.MEFs, two indepen-
dent tRNAi
Met.MEF clones, and a tRNAe
Met.MEF
clone. The number of mice that developed tumors
and the latency of onset are indicated in each case.
mas (Frye and Watt, 2006). Such obser-
vations support the contention that
tRNA metabolism can strongly influence
oncogenic transformation. Our data
provide evidence that elevated tRNA
production can have a causal role.
Levels of tRNAi
Met have been shown to
have a profound effect on cell prolifera-
tion inS. cerevisiae, with a 2-fold reduction in expression causing
a 3-fold slowing of doubling time (Francis and Rajbhandary,
1990). This can be explained if the availability of tRNAi
Met is
limiting for the overall rate of protein synthesis. Our data provide
clear evidence that this is indeed the case in mammalian fibro-
blasts, where modest overexpression of tRNAi
Met was found to
stimulate translation significantly. It is well-established that
biosynthesis and the attainment of adequate mass are essential
prerequisites for cell-cycle progression (Brooks, 1977; Johnston
et al., 1977; Sudbery, 2002). Since 80%–90% of a cell’s dry mass
is protein, the rate of translation is a major determinant of mass
accumulation and hence growth and proliferation (Zetterberg
and Killander, 1965). In some situations, rapid protein synthesis
can result in unbalanced growth and a change in cell size. This is
common in yeast and insects, but less so in mammals, where
growth and cell division show tighter coupling (Stocker and
Hafen, 2000). Indeed, we found only minor effects on cell volume
when Brf1 was induced, indicating that the effects on growth and
cell-cycle progression are balanced in this case.
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In principle, a global increase in protein synthesis may be
sufficient to drive cell growth and proliferation. However, such
effects might also be due to more selective induction of specific
proteins. There is considerable evidence that stimulating transla-
tional capacity can cause a preferential increase in the synthesis
of growth factors, cell-cycle promoters, and oncoproteins, such
as VEGF, cyclin D1, and c-Myc (Mamane et al., 2004). The ratio-
nale for this phenomenon is that mRNAs encoding such proteins
frequently contain highly structured 50-untranslated regions; as
a consequence, these mRNAs are translated inefficiently and
are disproportionately sensitive to rates of protein synthesis,
when compared to most mRNAs encoding housekeeping prod-
ucts (Koromilas et al., 1992; Mamane et al., 2004). The prolifera-
tive and transforming activities of Brf1 and tRNAi
Met might there-
fore reflect selective downstream induction of one or more
specific proteins. Indeed, we found that Brf1.MEFs and
tRNAi
Met.MEFs express elevated levels of cyclin D1 and c-Myc
proteins without a corresponding change in their mRNAs. These
products might contribute substantially to the observed pheno-
typic effects.
We have used induction of Brf1 as a tool to raise pol III
transcription. In so doing, we are mimicking a situation that
has been encountered in human cancers. A small study of cervi-
cal carcinoma biopsies found that a subset display abnormally
high levels of Brf1 mRNA (Daly et al., 2005). Furthermore,
ONCOMINE (www.oncomine.org), a web-based microarray
database and data-mining platform (Rhodes et al., 2004), iden-
tifies two independent studies of bladder and prostate carcino-
mas in which Brf1 is expressed at elevated levels in tumors rela-
tive to normal tissue. In such cancers, Brf1 may be exerting
significant proliferative and oncogenic effects, as we have ob-
served in cultured cells. The gene encoding Brf1 was identified
as a target for transcriptional induction by c-Myc in colonic epi-
thelium (Sansom et al., 2007). Elevated Brf1 expression may
therefore be a common feature of the many tumors in which
c-Myc is activated. This raises the possibility of positive feed-
back since we found translational induction of c-Myc when pro-
tein synthesis increases in response to Brf1. Pol III transcription
is also stimulated directly by c-Myc (Gomez-Roman et al., 2003).
We have shown that RNAi-mediated knockdown of Brf1
mRNA can inhibit focus formation by colon carcinoma cells.
Targeting the pol III machinery might therefore have therapeutic
potential. It has been suggested that repression of pol III
transcription may be important for the tumor suppression func-
tion of RB (Nasmyth, 1996; Larminie et al., 1998; Neufeld and
Edgar, 1998). Our data provide support for this contention.
EXPERIMENTAL PROCEDURES
Inducible Cell Lines
Expression construct pTRE2-Brf1 contains human Brf1 cDNA cloned into
pTRE2 vector (Clontech). The recipient mouse embryonic fibroblast (MEF/
3T3) line and Chinese hamster ovary (CHO) Tet-Off cells (Clontech) that
express the tetracycline-controlled transactivator were cultured in DMEM
or a-MEM, respectively, supplemented with 10% doxycycline-free FCS
(Clontech), 2 mM L-glutamine, 100 U/ml penicillin, 100 U/ml streptomycin,
and 100 mg/ml G418 sulfate. The MEF/3T3 line was established from primary
MEFs by spontaneous immortalization after culture according to the standard
3T3 protocol (3 day transfer, 3 3 105 cell inoculum). Cells were transfected
ET
Rusing Lipofectamine (Invitrogen) when 70%–80% confluent with 17 mg of
pTRE2-Brf1 plus 2 mg of the hygromycin resistance plasmid pTK-Hyg
(Clontech). After 48 hr, medium was supplemented with 2 mg/ml doxycycline
and 400 mg/ml hygromycin B (Melford Laboratories). After 2–4 weeks, hygrom-
ycin-resistant colonies were picked and screened for Brf1 induction. For
routine culture, medium was supplemented with 100 mg/ml hygromycin B
instead of 400 mg/ml that was used during the selection. To induce Brf1
expression, cells were washed twice in prewarmed PBS and cultured without
doxycycline.
Fragments containing tRNAMet genes were PCR amplified from mouse
genomic DNA with primer pairs 50-ATCCTTCGGAGCTCATTTTG-30 and 50-GC
GCTTCGAGATGTTTTCATC-30 for tRNAi
Met and 50-GCCATTGTGTCTGTTGAT
GG-30 and 50-GTCCAGGTCCGCTTAGAACAC-30 for tRNAe
Met. These frag-
ments were cloned into p-GEM-T Easy vector (Promega). Stably transfected
MEFs were established as above, except without doxycycline.
Adenovirus-Mediated Brf1 Expression
GFP-tagged replication-deficient adenovirus expressing HA-tagged human
Brf1 was constructed and produced as previously (Goodfellow et al., 2006).
MEF/3T3 cells were infected at an moi of 1.5 for 8 hr, after which the culture
medium was replaced. Immunofluorescence analysis confirmed that trans-
duced genes were expressed in >95% of cells within 36 hr.
Immunoblotting
Cell lysates were prepared and immunoblotting performed as previously
(Goodfellow et al., 2006; White et al., 1995) using antibodies 58C9 against
TBP, F-7 against HA, 9E10 against c-Myc, 72-13G against cyclin D1, C11
against actin (Santa Cruz Biotechnologies), 482 and 128 against Brf1 (Cairns
and White, 1998), 2663 against Bdp1 (Fairley et al., 2003), and C39 against
RPC39 (Jones et al., 2000). Antibody 482 was raised by immunizing rabbits
with synthetic peptide IDDLEIDRYILNESE (residues 452–466 of human Brf1).
RT-PCR Analysis
RNA was extracted using TRI reagent (Sigma), according to the manufac-
turer’s specifications. Reverse transcription was for 1 hr at 42C with 1 mg of
RNA, 200 ng of random hexamers (Promega), and 400U of reverse transcrip-
tase (Life Technologies) in 40 ml of 13 First Strand Buffer (Life Technologies)
containing 10 mM DTT and each dNTP at 0.5 mM. CDNA (1 ml) was amplified
in the presence of 1.85 mCi of [a-32P] dCTP using 20 pmol of primers. Primers
and amplification conditions are described in the Supplemental Data.
ChIP Assays
ChIP was performed as previously using published primers and amplification
procedures (Fairley et al., 2005; Gomez-Roman et al., 2003). Antibodies were
M19 against TAFI48 and C-18 against TFIIB (Santa Cruz Biotechnologies), 128
against Brf1 (Cairns and White, 1998), and 1900 against RPC155 (Fairley et al.,
2003). Serial dilutions of input chromatin were used to establish that PCRs
were within a linear range.
Translation, Apoptosis, Proliferation, and Cell-Cycle Analysis
To measure protein synthesis, 2 3 103 cells were inoculated into each well of
a 24-well plate. 5 mCi of 35S-Met and 35S-Cys was added per ml of medium 1 hr
before harvesting; incorporation of radiolabel into acid-insoluble material was
determined, as described (Goodfellow et al., 2006).
To measure proliferation, 73 104 cells were inoculated into 10 cm dishes in
the presence or absence of 2 mg/ml doxycycline. Medium and doxycycline
were renewed every 48 hr. Numbers of viable cells were counted each day
after trypan blue (Sigma) staining.
For cell-cycle analysis, MEFs were plated at a density of 105 cells per 10 cm
dish and cultured for 48 hr before washing twice in PBS and harvesting with
5 ml cell dissociation buffer (Sigma). Cells were pelleted by centrifuging at
1000 rpm for 3 min, washed twice in PBS, and then fixed by adding 1 ml of
ice-cold 1:1 (v/v) PBS/ethanol in a drop-wise fashion, with gentle agitation.
On the day of analysis, fixed cells were washed twice with PBS, resuspended
in RNase A (Sigma, 50 mg/ml) and propidium iodide (PI, Sigma, 10 mg/ml), and
incubated in the dark at room temperature for 1 hr before flow cytometric
sorting (Beckmann).
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MEFs were transfected at 40% confluence to a final concentration of 50 nM
siRNA oligonucleotides, delivered using Lipofectamine 2000 (Invitrogen).
Medium was replaced after 5 hr and cells were harvested after a further
48 hr. SiRNAs were all from Ambion: RPC39 si1 50-GGAAAAACUGGUCUAUC
AA-30; RPC39 si2 50- GGAUUCUCAGAAUGCUGGU-30; GFP (cycle 3); c-Myc
50-GGAGGAACGAGCUAAAACG-30; Brf1 si1 50-GGAAGAUCUGUUGUU
ACUU-30; Brf1 si2 50-CCCGUGCCUGUAUAUUCCA-30.
Transformation Assays
For focus formation, cells were seeded at a density of 33 105 per 10 cm plate
and then grown to confluency in the presence or absence of doxycycline.
Cultures were maintained for a further 3 weeks after reaching confluency,
with the media changed every 4 days. After 3 weeks, the cells were washed
twice with PBS and once with ice-cold methanol and then fixed for 10 min in
methanol before being stained with 0.1% (w/v) methylene blue (Sigma) and
photographed.
To measure saturation density, cells were seeded as above, cultured for
24 hr before withdrawal of doxycycline, as appropriate, and then grown to con-
fluency. Cell numbers were determined after trypsinization by counting in a
haemocytometer.
To assay anchorage-independent growth, 53 103 cells in 0.35% (w/v) agar
containing 20% (v/v) FCS were overlaid onto 0.5% (w/v) agar in a 35 mm plate.
Plates were overlaid with 0.35% (w/v) agar with or without 2 mg/ml doxycycline
every 2 days. Colonies were stained with 0.005% (w/v) crystal violet and then
photographed.
To measure tumorigenic potential in vivo, MEFs were injected into athymic
mice. A total of 2 3 106 cells from each MEF clone were suspended in HEPES
Buffered Saline (Sigma) and injected subcutaneously into each flank of an
animal. After injection, mice were monitored three times/week for tumor forma-
tion. Once detected, tumor dimensions were measured three times/week with
callipers. Animals with tumor volumes in excess of 1200 mm3 were sacrificed.
HCT116 cells were plated at a density of 7 3 105 cells per 10 cm dish in
McCoy’s 5A (GIBCO) supplemented with 10% FBS (Sigma), 2 mM L-gluta-
mine, 100 U/ml streptomycin, and 100 U/ml penicillin. After 2 and 5 days,
they were transfected with siRNAs to a final concentration of 100 nM. Lysates
were prepared for immunoblotting after a further 2 days. Staining for foci was
carried out as above, 14 days after plating.
SUPPLEMENTAL DATA
Supplemental Data include Experimental Procedures, References, and four
figures and can be found with this article online at http://www.cell.com/cgi/
content/full/133/1/78/DC1/.
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